| Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock |
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. |
zacks.com |
2025-05-12 13:50:56 |
Czytaj oryginał (ang.) |
| Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-09 14:46:19 |
Czytaj oryginał (ang.) |
| PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates |
Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss of 5 cents per share. |
zacks.com |
2025-05-09 13:50:44 |
Czytaj oryginał (ang.) |
| Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript |
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Operator Good afternoon. My name is Sherry, and I will be your conference call operator today. |
seekingalpha.com |
2025-05-09 13:08:15 |
Czytaj oryginał (ang.) |
| Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates |
Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. |
zacks.com |
2025-05-08 23:00:47 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports First Quarter Financial Results |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results. |
businesswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards t. |
businesswire.com |
2025-05-06 21:15:00 |
Czytaj oryginał (ang.) |
| Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know |
Puma Biotech (PBYI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2025-04-30 17:00:40 |
Czytaj oryginał (ang.) |
| Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients |
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis. |
globenewswire.com |
2025-04-30 10:00:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025. |
businesswire.com |
2025-04-28 19:03:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET. |
businesswire.com |
2025-04-24 20:11:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Puma Biotechnology (PBYI) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-04-23 14:45:50 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Puma Biotechnology Stock? |
Investors need to pay close attention to PBYI stock based on the movements in the options market lately. |
zacks.com |
2025-04-21 14:15:40 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-04-02 21:15:00 |
Czytaj oryginał (ang.) |
| Puma SE: Undervalued With Tailwinds Ahead |
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performance, Puma's robust dividend growth history and stable payout ratio indicate a solid foundation for future shareholder returns. My DCF analysis reveals that Puma is undervalued, with an intrinsic value per share of $5.35, representing a 78.3% upside from current levels. |
seekingalpha.com |
2025-03-31 08:53:07 |
Czytaj oryginał (ang.) |
| Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting. |
businesswire.com |
2025-03-26 11:00:00 |
Czytaj oryginał (ang.) |
| PUMA SE: This Is The Right Time To Buy |
Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenue growth, Puma has struggled with profitability as rising operating expenses have outpaced sales, leading to stagnant net income over the past several years. High-profile collaborations with cultural icons like Rihanna, A$AP Rocky, and top sports teams such as Scuderia Ferrari's F1 team are driving increased brand engagement and market relevance. |
seekingalpha.com |
2025-03-21 09:46:22 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards t. |
businesswire.com |
2025-03-05 20:05:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The. |
businesswire.com |
2025-03-05 19:30:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference |
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will provide an overview of Puma Biotechnology at the Barclays Annual Global Healthcare Conference at 2:00 p.m. ET on March 11. |
businesswire.com |
2025-03-05 18:11:00 |
Czytaj oryginał (ang.) |
| Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates |
Puma Biotech (PBYI) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.31 per share a year ago. |
zacks.com |
2025-02-27 21:25:33 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results. |
businesswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marriott Copley Place in Boston. A live webcast of the presentation will be available on the Puma Biotechnology website at ht. |
businesswire.com |
2025-02-26 18:15:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m. PT/4:30 p.m. ET. |
businesswire.com |
2025-02-13 18:15:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 7,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awar. |
businesswire.com |
2025-02-05 19:05:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 6th |
NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024. |
zacks.com |
2025-01-06 13:35:43 |
Czytaj oryginał (ang.) |
| Best Value Stocks to Buy for January 6th |
AHT, PBYI and CWD made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2024. |
zacks.com |
2025-01-06 06:01:08 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 24,375 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awar. |
businesswire.com |
2025-01-03 19:15:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy |
Puma Biotech (PBYI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-01-01 15:15:48 |
Czytaj oryginał (ang.) |
| Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-01 12:51:25 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why |
Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise. |
zacks.com |
2024-12-27 13:11:46 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for December 24th |
PBYI, DDS and NJR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 24, 2024. |
zacks.com |
2024-12-24 13:16:10 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 24th |
FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024. |
zacks.com |
2024-12-24 08:51:09 |
Czytaj oryginał (ang.) |
| Best Value Stocks to Buy for December 24th |
PBYI, DDS and PINC made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 24, 2024. |
zacks.com |
2024-12-24 06:16:10 |
Czytaj oryginał (ang.) |
| Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation |
LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A. |
businesswire.com |
2024-12-23 11:01:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward |
Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain. |
seekingalpha.com |
2024-12-16 13:36:23 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-12-04 19:15:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Puma Biotechnology (PBYI) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-28 12:41:16 |
Czytaj oryginał (ang.) |
| PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer |
Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer. |
zacks.com |
2024-11-21 14:16:09 |
Czytaj oryginał (ang.) |
| PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up |
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. |
zacks.com |
2024-11-08 13:35:17 |
Czytaj oryginał (ang.) |
| Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript |
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer Conference Call Participants Ed White - H.C. Wainwright Divya Rao - TD Cowen Operator Good afternoon. |
seekingalpha.com |
2024-11-08 01:09:06 |
Czytaj oryginał (ang.) |
| Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates |
Puma Biotech (PBYI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.17 per share a year ago. |
zacks.com |
2024-11-07 21:41:12 |
Czytaj oryginał (ang.) |
| Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 5,625 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award. |
businesswire.com |
2024-11-05 19:15:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ: PBYI) and Encourages Investors to Contact the Firm |
PHILADELPHIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Puma Biotechnology, Inc. (“Puma”) (NASDAQ: PBYI) on behalf of the company's shareholders. |
globenewswire.com |
2024-10-29 10:30:00 |
Czytaj oryginał (ang.) |
| Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected |
Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line. |
zacks.com |
2024-08-02 15:10:53 |
Czytaj oryginał (ang.) |
| Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript |
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Marc Frahm - TD Cowen Ed White - H.C. Wainwright Operator Good afternoon. |
seekingalpha.com |
2024-08-02 02:54:07 |
Czytaj oryginał (ang.) |
| Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates |
Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.10 per share a year ago. |
zacks.com |
2024-08-01 23:11:20 |
Czytaj oryginał (ang.) |